Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim

By Motif July 26, 2019 No Comments

Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim

https://www.motifbio.com/wp-content/uploads/2019/07/20190726_FINAL_MTFB-PR_FDA-Type-B-mtg-date.pdf

Get MotifBio Email Alerts Subscribe

About Us

Motif Bio is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA.

Navigation

About Motif
Iclaprim
Investors
News Releases
Contact Us

Contact Us

Motif Bio plc
201 Temple Chambers
3-7 Temple Avenue
London EC4Y 0DT
United Kingdom

Motif BioSciences Inc.
125 Park Avenue, 25th Floor
New York, NY 10017
United States
General: info@motifbio.com
Investors: ir@motifbio.com

Home
About
Development Programs
Partnering
Investors
Contact

Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim